Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Ark Therapeutics reviews 2010 business progress

Ark Therapeutics reviews 2010 business progress

18th May 2010

Ark Therapeutics has published its interim management statement for 2010 to date, during which the company has been able to make progress towards several key targets.

According to the report, the healthcare firm has been able to conclude its strategic review in the first four months of this year having successfully implemented a number of restructuring and cost reduction measures.

In addition, the company has been able to maintain a strong level of sales growth in its woundcare division, while also reporting positive trial results for its first novel neuropilin 1 antagonists for cancer treatment.

Ark will now be looking to press ahead with ongoing projects, such as its efforts to secure regulatory approval for its Cerepro treatment.

It also agreed a preferred supplier memorandum with Merck Sharpe and Dohme earlier this year which will see it manufacture gene-based medicinal products for the pharmaceuticals firm.

Martyn Williams, chief executive officer of Ark, said: “With the company repositioned to generate value from its attractive portfolio of assets, management is focused on delivering tangible value for our shareholders in the near term.”

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.